This trial is evaluating whether Mi Quit Care will improve 1 primary outcome and 1 secondary outcome in patients with Tobacco Use Cessation. Measurement will happen over the course of 6 months.
This trial requires 506 total participants across 2 different treatment groups
This trial involves 2 different treatments. Mi Quit Care is the primary treatment being studied. Participants will all receive the same treatment. There is no placebo group. The treatments being tested are not being studied for commercial purposes.
Results from a recent paper of this meta-analysis demonstrate that the use of nicotine gum is effective at aiding in nicotine dependence relief and has shown to be more effective than the use of a placebo. Results from a recent paper provide further insight into potential benefits of nicotine treatment in patients with nicotine dependence in order to alleviate withdrawal symptoms and, over time, decrease the level of dependence on nicotine.
Participants in the trial have a unique opportunity to engage in a meaningful and supportive health behavior change that they might not otherwise have undertaken. A clinical researcher must be well-informed about the patient-relevant and health-relevant characteristics of tobacco use cessation. These include age, gender, race, ethnicity, socioeconomic background, marital status, co-morbidity status, smoking habit, and smoking history. If clinical researchers have the necessary knowledge it is important that they have adequate training that incorporates smoking cessation interventions in their skill set.
Tobacco use cessation is important for the protection against coronary heart disease, and the signs of this are smoking cessation, not only in a partner or spouse, in childhood and adolescence, avoiding tobacco among people of all ages and all socioeconomic groups, and being careful of the health and medical status such as weight, nutrition, and exercise of family members and friends.
Results from a recent clinical trial indicates that tobacco use cessation is not currently curable; however, it is possible to help individuals stop using tobacco by providing evidence-based health and social counseling and providing other forms of motivation to quit.
The most popular form of smoking cessation is nicotine replacement therapy. If a physician and patient feel no benefit and the desire is still present, another method should be attempted, such as bupropion. Other options to encourage a non-smoking lifestyle include lifestyle change counseling and behavioral therapy. Alcoholics may be encouraged to get proper medical care and medication for their alcohol intake. Alcoholics do have a possibility to become abstinent and this can be achieved with many methods. Most of the treatments for alcohol abuse include lifestyle changes to help the person feel better about themselves and stay away from alcohol. The only option available for those who cannot stop using alcohol completely is quitting.
There is a strong desire to quit using tobacco both before and post cessation. This is the result of many contributing factors. This warrants implementing an individual, culturally relevant, comprehensive and multidisciplinary program of smoking cessation to effectively curb the use of tobacco.
More than 37 million adults are receiving no intervention targeting tobacco use cessation in the United States. More than half of those who receive no intervention receive a one-off intervention with a quit attempt. More than 50% receive a follow-up quit attempt after the intervention.
For adult smokers, the average age was 50 years. For current smokers the average age was 43 years. For former smokers, the average age was 32 years. Overall, women have a median age of 35 years, men have a median of 41 years. [Power] helps with research questions regarding treatment options and prevention for tobacco use cessation. These questions can help clinicians identify and treat more smokers. [Power] also makes it fast and easy to compare age and experience in treatment options across providers. [Power] also helps clinicians identify other possible diagnoses that could mimic tobacco use cessation.
As tobacco use is a multifactorial risk factor for health, these results suggest multiple strategies that are required to aid tobacco users in smoking cessation. However, the high percentage of current smokers and their social networks (i.e., family and friends) suggest that the social environment can play an important role in the effectiveness of smoking cessation. Hence, interventions aimed at encouraging tobacco users to stay linked to family and friends to ensure that social support persists during smoking cessation can help smokers to experience more sustained effectiveness.
There are many studies on [smoking cessation](https://www.withpower.com/clinical-trials/smoking-cessation) and they are more and more prevalent in the health literature. There is still a need for the research and recommendations on the most appropriate way to support smoking cessation in general practitioners' practices, as well as helping patients to stay abstinent from smoking if they wish to get better health.
A novel, effective smoking reduction product called SmartQUIT provides a significant increase in success rates in smoking cessation programmes for patients who do not have access to smoking cessation medication. This product has the potential to improve outcomes in smokers in resource-constrained settings.
More than half of patients who smoke cessation were not able to achieve their aim. It is important to support smokers and encourage them to overcome their first experience with quitting, as they would be more likely to succeed in the long run. They might also benefit from a smoking cessation programme which facilitates self-help skills acquisition.